T-Cell PET Imaging With [18F]F-AraG in Lung Cancer
Status:
Withdrawn
Trial end date:
2019-10-15
Target enrollment:
Participant gender:
Summary
This is a single-center cross-sectional imaging study in patients with localized lung cancer
undergoing immunotherapy with or without stereotactic radiation therapy as part of the
companion clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for
Non-Small Cell Lung Cancer). Each patient will undergo a single [18F]F-AraG PET exam as part
of this study. [18F]F-AraG will be administered at a single time point intravenously prior to
PET imaging. Whole-body PET will be acquired along with a whole body low dose CT (PET/CT)
used for attenuation correction and anatomic localization of [18F]F-AraG uptake, SUV
calculation, and volumetric selection for radiomic analyses.